Kidney transplantation in patients with Fabry disease
- 1 April 2009
- journal article
- research article
- Published by Frontiers Media SA in Transplant International
- Vol. 22 (4), 475-481
- https://doi.org/10.1111/j.1432-2277.2008.00824.x
Abstract
Little is known about the effects of enzyme replacement therapy (ERT) in kidney transplant recipients with Fabry disease. Clinical characteristics of transplant recipients in the Fabry Outcome Survey (FOS) were therefore examined in patients with Fabry disease with or without ERT. Of the 837 European patients in FOS (March 2006), 34 male patients and two female patients had received kidney transplants. Mean age at transplantation was 37.6 +/- 10.9 years, mean time since transplantation was 7.7 +/- 6.4 years, median estimated glomerular filtration rate (eGFR) was 44.4 ml/min/1.73 m(2), and median proteinuria was 296 mg/24 h. Of 27 patients with baseline data, 59% had hypertension, 74% had left ventricular hypertrophy, 22% had cardiac valve disease, 30% had arrhythmia, and 22% had transient ischaemic attacks and 15% stroke. Twenty patients (74%; two female patients, 18 male patients) were receiving ERT with agalsidase alfa. At enrollment or at the start of ERT, median eGFRs were 59 and 35 ml/min/1.73 m(2) (P = 0.05) and median proteinuria levels were 240 and 420 mg/24 h (not significant) in treated and untreated patients respectively. Renal function remained stable in patients receiving ERT. In conclusion, agalsidase alfa is well tolerated in patients with Fabry disease who have undergone renal transplantation.Keywords
This publication has 23 references indexed in Scilit:
- Chronic Renal Failure and Proteinuria in Adulthood: Fabry Disease Predominantly Affecting the KidneysAmerican Journal of Kidney Diseases, 2005
- Fabry disease: overall effects of agalsidase alfa treatmentEuropean Journal of Clinical Investigation, 2004
- The Mainz Severity Score Index: a new instrument for quantifying the Anderson–Fabry disease phenotype, and the response of patients to enzyme replacement therapyClinical Genetics, 2004
- Natural History and Treatment of Renal Involvement in Fabry DiseaseJournal of the American Society of Nephrology, 2002
- Anderson-Fabry DiseaseJournal of the American Society of Nephrology, 2002
- Advances in the management of Anderson–Fabry disease:enzyme replacement therapyExpert Opinion on Biological Therapy, 2002
- Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier femalesJournal of Medical Genetics, 2001
- Natural history of Fabry disease in affected males and obligate carrier femalesJournal of Inherited Metabolic Disease, 2001
- Early renal changes in hemizygous and heterozygous patients with Fabry's diseaseKidney International, 1978
- Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae)Archiv für dermatologische Forschung, 1898